Pralatrexate(Folotyn) is an antifolate, and structurally a folate analog.
Cat.No
DC9359
Name
Pralatrexate
Chemical Properties
CAS
146464-95-1
Formula
C23H23N7O5
MW
477.4726
Storage
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
References
[1]. Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA.,Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study,Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. Epub 2012 Apr 26.
[2]. Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD.,Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.,J Thorac Oncol. 2012 Jun;7(6):1041-8.
[3]. Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M.,Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.,Blood. 2012 May 3;119(18):4115-22. Epub 2012 Mar 6.
[4]. Casanova M, Medina-Pérez A, Moreno-Beltran M, Mata-Vazquez M, Rueda A.,Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.,Ther Clin Risk Manag. 2011;7:401-8. Epub 2011 Oct 7.
[5]. Hui J, Przespo E, Elefante A.,Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.,J Oncol Pharm Pract. 2012 Jun;18(2):275-83. Epub 2011 Sep 26.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
